logo

Merus B.V. (MRUS)



Trade MRUS now with
  Date
  Headline
5/31/2019 7:35:35 AM Wedbush Is Raising Merus B.V. (MRUS) FY19 Rev. Estimate To 29.2 M From 16.6 M
5/31/2019 7:35:24 AM Wedbush Is Increasing Merus B.V. (MRUS) Q4 19 Rev. Estimate To 7.2 M From 4.2 M
5/31/2019 7:35:19 AM Wedbush Is Raising Merus B.V. (MRUS) Q3 19 Rev. Estimate To 7.2 M From 4.2 M
5/31/2019 7:35:06 AM Wedbush Is Raising Merus B.V. (MRUS) Q2 19 Rev. Estimate To 7.2 M From 4.2 M
5/31/2019 7:34:40 AM Wedbush Is Increasing Merus B.V. (MRUS) FY19 Estimate To -1.54 From -2.64
5/31/2019 7:34:28 AM Wedbush Is Raising Merus B.V. (MRUS) Q4 19 Estimate To -0.46 From -0.72
5/31/2019 7:33:54 AM Wedbush Is Increasing Merus B.V. (MRUS) Q3 19 Estimate To -0.40 From -0.66
5/31/2019 7:33:38 AM Wedbush Is Increasing Merus B.V. (MRUS) Q2 19 Estimate To -0.41 From -0.67
5/31/2019 7:33:04 AM Wedbush Reiterates Merus B.V. (MRUS) At Outperform With $25 Price Target
1/7/2019 7:03:34 AM Merus Says FDA Accepted IND Application For MCLA-145
1/3/2019 4:01:42 AM ProBioGen Says It Achieved Undisclosed Milestone Payment From Merus N.V.
1/2/2019 8:09:26 AM Merus Announces Strategic Collaboration With Betta Pharma To Develop And Commercialize MCLA-129 In China
12/27/2018 6:36:05 PM Merus Q3 Loss/share EUR 0.47 Vs. Loss EUR 0.69 Year Ago
8/10/2018 8:39:11 AM Merus Q2 Total Revenue €6.5 Mln Vs. €6.2 Mln Prior Year
5/24/2018 7:05:40 AM Merus Announces First Patient Dosed In Phase 1 Trial Of MCLA-158 In Patients With Solid Tumors
4/30/2018 9:20:55 AM Wedbush Is Increasing Merus B.V. (MRUS) FY18 Estimate To -3.29 From -3.78
4/30/2018 9:20:41 AM Wedbush Is Increasing Merus B.V. (MRUS) Q4 18 Estimate To -0.94 From -1.07
4/30/2018 9:20:26 AM Wedbush Is Raising Merus B.V. (MRUS) Q3 18 Estimate To -0.86 From -0.98
  
 
>